Nemolizumab for atopic dermatitis

Angelina Labib, Ashley Vander Does, Gil Yosipovitch

Research output: Contribution to journalReview articlepeer-review


Atopic dermatitis (AD) is a common inflammatory skin disease that has emerging treatments targeting the underlying immunological mechanism. Interleukin-31 (IL-31) is associated with the pathobiological mechanism of AD, contributing to symptoms such as dermatitis and pruritus. Nemolizumab is an anti-IL-31 receptor α-chain (IL-31RA) monoclonal antibody agent that is efficacious in improving symptoms of AD in several phase II and phase III studies in recent years. Nemolizumab demonstrates great efficacy in reducing pruritus and to a lesser degree, dermatitis associated with AD. Additionally, one advantage of nemolizumab is its quick speed of action. Adverse effects are mild and transient in nature, including exacerbation of AD, nasopharyngitis, upper respiratory tract infections, elevated creatine kinase and peripheral edema. Severe adverse effects were not common and consisted of exacerbation of AD and asthma exacerbation. Therefore, nemolizumab has the potential to be an important treatment of choice for AD given its efficacy, mild side effect profile and rapid time of onset. In this review, we examine the preclinical and clinical studies of the novel drug nemolizumab for the treatment of AD with a focus on its mechanism of action, pharmacokinetics, safety, efficacy, indications and drug interactions.

Original languageEnglish (US)
Pages (from-to)159-173
Number of pages15
JournalDrugs of Today
Issue number4
StatePublished - Apr 1 2022
Externally publishedYes


  • Anti-interleukin-31 receptor α-chain (IL-31RA) agents
  • Atopic dermatitis
  • Dermatological disorders
  • Monoclonal antibodies
  • Nemolizumab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Nemolizumab for atopic dermatitis'. Together they form a unique fingerprint.

Cite this